AstraZeneca COVID-19 Vaccine is a two-dose replication-deficient adenovirus vector vaccine used to prevent COVID-19 caused by SARS-CoV-2. The AstraZeneca COVID-19 Vaccine (previously known as ChAdOx1 nCoV-19 or AZD1222) is one of several vaccines developed in 2020 for the prevention of COVID-19 caused by SARS-CoV-2.
- Mechanism
- Curator reviewed · 1 reference
The AstraZeneca COVID-19 Vaccine is a replication-deficient (i.e. inactivated) chimpanzee adenovirus vector - specifically the ChAdOx1 vector - encoding a trimeric pre-fusion form of the SARS-CoV-2 spike (S) protein. Following intramuscular administration these spike proteins are expressed locally, allowing the immune system to mount a neutralizing antibody/cellular immune response. This initial exposure and priming of the immune system subsequently provides protection against future infection.
- Primary indication
- The AstraZeneca COVID-19 Vaccine is indicated for the active immunization of individuals 18 years of age and older for the prevention of COVID-19.Curator reviewed · 1 structured indication
- First approval
- Canada, 2021
- Also known as
- ChAdOx-1-S[recombinant] · ChAdOx1 nCoV-19 · ChAdOx1-S [recombinant]
- Code names
- AZD-1222
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with AstraZeneca COVID-19 Vaccine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account